Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: Hospital Israelita Albert Einstein
Collaborators: AstraZeneca